ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1299

Rheumatoid Arthritis Patients Who Never Use a Biological During Their Disease Course Represent a Subgroup of Patients Likely to Achieve Sustained DMARD-free Remission
Abstract Number: 1300

Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression
Abstract Number: 1301

The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis
Abstract Number: 1302

Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study
Abstract Number: 1303

Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis
Abstract Number: 1304

Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy
Abstract Number: 1305

Variations in Macrophage Cholesterol Loading over Time Are Linked to Dynamic Changes in Coronary Atherosclerotic Plaque in Rheumatoid Arthritis
Abstract Number: 1306

Statin Use Attenuates the Impact of Systemic Inflammation on Ischemic Cardiovascular Risk in Patients with Rheumatoid Arthritis
Abstract Number: 1307

Impact of Comorbidities on the First bDMARD Effectiveness and Retention Rate After 2 Years of Follow-up in Patients with Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER
Abstract Number: 1308

Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study
Abstract Number: 1309

Refractory RA Patients for Targeted Therapies in Real Life
Abstract Number: 1310

Comparison of Two Methotrexate Initiation Strategies in Rheumatoid Arthritis in Current Practice
Abstract Number: 1311

T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Abstract Number: 1312

Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Abstract Number: 1313

Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].